MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
36.42
+0.03
+0.08%
Closed 17:10 02/14 EST
OPEN
37.44
PREV CLOSE
36.39
HIGH
38.00
LOW
36.36
VOLUME
839.82K
TURNOVER
0
52 WEEK HIGH
70.13
52 WEEK LOW
30.17
MARKET CAP
6.68B
P/E (TTM)
-19.0871
1D
5D
1M
3M
1Y
5Y
1D
Peering Into Legend Biotech's Recent Short Interest
Benzinga · 17h ago
Weekly Report: what happened at LEGN last week (0210-0214)?
Weekly Report · 23h ago
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?
NASDAQ · 4d ago
Weekly Report: what happened at LEGN last week (0203-0207)?
Weekly Report · 02/10 09:27
How The Parts Add Up: KOMP Headed For $62
NASDAQ · 02/04 12:28
Weekly Report: what happened at LEGN last week (0127-0131)?
Weekly Report · 02/03 09:28
SA Asks: Which Big Pharmas would be most impacted by higher tariffs?
Seeking Alpha · 02/01 17:30
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Seeking Alpha · 01/30 22:03
More
About LEGN
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.